Cell adhesion: Implication in tumor progression

Minerva Medica

Volumn 101, Issue 3, 2010, Pages 149-162

  Zigler, M ^a   Dobroff, A S ^a   Bar Eli, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell adhesion molecules; Neoplasms; Therapeutics

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALPHA2 INTEGRIN; ALPHA6 INTEGRIN; ALPHA6BETA4 INTEGRIN; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BETA1 INTEGRIN; BETA4 INTEGRIN; BIOLOGICAL MARKER; CD146 ANTIGEN; DOXORUBICIN CYCLIC ARGINYLGLYCYLASPARTIC ACID CONJUGATE; DOXORUBICIN DERIVATIVE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17 E6; MONOCLONAL ANTIBODY ABX MA 1; NERVE CELL ADHESION MOLECULE; P CADHERIN; PADGEM PROTEIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 1; VERY LATE ACTIVATION ANTIGEN 2; VERY LATE ACTIVATION ANTIGEN 3; VERY LATE ACTIVATION ANTIGEN 4;

CANCER CELL; CANCER INVASION; CELL ADHESION; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; METASTASIS; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CADHERINS; CELL ADHESION; CELL ADHESION MOLECULES; CELL COMMUNICATION; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULINS; INTEGRINS; NEOPLASM PROTEINS; NEOPLASMS; SELECTINS;

EID: 77957659047     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (114)

1. Johnson JP. Cell adhesion molecules in the development and progression of malignant melanoma. Cancer Metastasis Rev 1999;18:345-57.
2. Cavallaro U, Christofori G. Cell adhesion and signalling by Cadherins and IgSF-CAMs in cancer. Nat Rev Cancer 2004;4:118-32. (Pubitemid 38198740)
3. Zetter BR. Adhesion molecules in tumor metastasis. Semin Cancer Biol 1993;4:219-29.
4. Luo BH, Carman CV, Springer TA. Structural basis of integrin regulation and signaling. Annu Rev Immunol 2007;25:619-47.
5. Stupack DG. The biology of integrins. Oncology (Williston Park) 2007;21:6-12.
6. van der Flier A, Sonnenberg A. Function and interactions of integrins. Cell Tissue Res 2001;305:285-98.
7. Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr Opin Cell Biol 1999;11:737-44.
8. Colombatti A, Bonaldo P, Doliana R. Type A modules:interacting domains found in several non-fibrillar collagens and in other extracellular matrix proteins. Matrix 1993;13:297-306.
9. Reddy KV, Mangale SS. Integrin receptors:the dynamic modulators of endometrial function. Tissue Cell 2003;35:260-73.
10. Jin H, Varner J. Integrins.roles in cancer development and as treatment targets. Br J Cancer 2004;90:501-5.
11. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev 29:223-37.
12. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8:604-17.
13. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009;122:159-63.
14. Olsen IM, Ffrench-Constant C. Dynamic regulation of integrin activation by intracellular and extracellular signals controls oligodendrocyte morphology. BMC Biol 2005;3:25. (Pubitemid 41684575)
15. Legate KR, Wickstrom SA, Fassler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev 2009;23:397-418.
16. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
17. Giancotti FG. Integrin signaling:specificity and control of cell survival and cell cycle progression. Curr Opin Cell Biol 1997;9:691-700. (Pubitemid 27424926)
18. Bon G, Folgiero V, Di Carlo S, Sacchi A, Falcioni R. Involvement of alpha6beta4 integrin in the mechanisms that regulate breast cancer progression. Breast Cancer Res 2007;9:203.
19. Guo W, Pylayeva Y, Pepe A, Yoshioka T, Muller WJ, Inghirami G et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006;126:489-502.
20. Marconi, A. et al. FLICE/caspase-8 activation triggers anoikis induced by beta1-integrin blockade in human keratinocytes. J Cell Sci 2004;117:5815-23.
21. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001;155:459-70. (Pubitemid 34289336)
22. Ruegg C, Alghisi GC. Vascular integrins:therapeutic and imaging targets of tumor angiogenesis. Recent Results Cancer Res 180:83-101.
23. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis:mediators and therapeutic targets. Endothelium 2006;13:113-35.
24. Lipscomb EA, Simpson KJ, Lyle SR, Ring JE, Dugan AS, Mercurio AM. The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo. Cancer Res 2005;65:10970-6.
25. De S, Razorenova O, McCabe NP, O'Toole T, Qin J, Byzova TV. VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci U S A 2005;102:7589-94.
26. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
27. Pécheur I, Peyruchaud O, Serre CM, Guglielmi J, Voland C, Bourre F et al. Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. Faseb J 2002;16:1266-8.
28. Goel HL, Li J, Kogan S, Languino LR. Integrins in prostate cancer progression. Endocr Relat Cancer 2008;15:657-64.
29. Deryugina EI, Bourdon MA, Luo GX, Reisfeld RA, Strongin A. Matrix metalloproteinase-2 activation modulates glioma cell migration. J Cell Sci 1997;110(Pt 19):2473-82. (Pubitemid 127699161)
30. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases:regulators of the tumor microenvironment. Cell 141:52-67.
31. Iyer V, Pumiglia K, DiPersio CM. Alpha3beta1 integrin regulates MMP-9 mRNA stability in immortalized keratinocytes:a novel mechanism of integrin-mediated MMP gene expression. J Cell Sci 2005;118:1185-95.
32. Maity G, Sen T, Chatterjee A. Laminin induces matrix metalloproteinase-9 expression and activation in human cervical cancer cell line (SiHa). J Cancer Res Clin Oncol. 2010 Apr 28. [Epub ahead of print]
33. Hofmann UB, Westphal JR, Van Muijen GN, Ruiter DJ. Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000;115:337-44.
34. Liu AJ, Hu YX, Liu CJ, Yao XL, Zhang GR. The mechanism of inhibition of metastasis by cartilage polysaccharide in breast-cancer cells. Biotechnol Appl Biochem 2009;53:253-63.
35. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010;11:97-105.
36. Cominetti MR, Martin AC, Ribeiro JU, Djaafri I, Fauvel-Lafève F, Crépin M et al. Inhibition of platelets and tumor cell adhesion by the disintegrin domain of human ADAM9 to collagen I under dynamic flow conditions. Biochimie 2009;91:1045-52.
37. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001;98:1853-8.
38. Makrilia N, Kollias A, Manolopoulos L, Syrigos K. Cell adhesion molecules:role and clinical significance in cancer. Cancer Invest 2009;27:1023-37.
39. Perez-Moreno M, Jamora C, Fuchs E. Sticky business:orchestrating cellular signals at adherens junctions. Cell 2003;112:535-48.
40. Yagi T, Takeichi M. Cadherin superfamily genes:functions, genomic organization, and neurologic diversity. Genes Dev 2000;14:1169-80. (Pubitemid 30327498)
41. Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008;4:835-50.
42. Takeichi M. Cadherins:a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990;59:237-52.
43. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol 1997;13:119-46.
44. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer:how does Cadherin dysfunction promote tumor progression? Oncogene 2008;27:6920-9.
45. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000;2:84-9.
46. Wheelock MJ, Soler AP, Knudsen KA. Cadherin junctions in mammary tumors. J Mammary Gland Biol Neoplasia 2001;6:275-85.
47. N Nawrocki-Raby B, Gilles C, Polette M, Bruyneel E, Laronze JY, Bonnet N et al. Upregulation of MMPs by soluble E-cadherin in human lung tumor cells. Int J Cancer 2003;105:790-5.
48. Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG. Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 2000;275:2727-32.
49. Chan AO, Lam SK, Wong BC, Wong WM, Yuen MF, Yeung YH et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003;52:502-6.
50. Reinhold WC, Reimers MA, Lorenzi P, Ho J, Shankavaram UT, Ziegler MS et al. Multifactorial regulation of E-cadherin expression:an integrative study. Mol Cancer Ther 9:1-16.
51. Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res 2002;62:1613-8.
52. Sánchez-Tilló E, Lázaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010 Apr 26. [Epub ahead of print].
53. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology 2009;137:361-71, 71 e1-5.
54. Perez-Moreno MA, Locascio A, Rodrigo I, Dhondt G, Portillo F, Nieto MA et al. A new role for E12/E47 in the repression of E-cadherin expression and epithelial-mesenchymal transitions. J Biol Chem 2001;276:27424-31.
55. Rodriguez M, Aladowicz E, Lanfrancone L, Goding C.R. Tbx3 represses E-cadherin expression and enhances melanoma invasiveness. Cancer Res 2008;68:7872-81.
56. Schwartz B, Melnikova VO, Tellez C, Mourad-Zeidan A, Blehm K, Zhao YJ et al. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo. Oncogene 2007;26:4049-58.
57. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
58. Noë V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001;114:111-8.
59. Cavallaro U, Christofori G. Multitasking in tumor progression:signaling functions of cell adhesion molecules. Ann N Y Acad Sci 2004;1014:58-66. (Pubitemid 38594791)
60. Gottardi CJ, Gumbiner BM. Distinct molecular forms of beta-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol 2004;167:339-49.
61. Vincan E, Barker N. The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis 2008;25:657-63.
62. Qian X, Karpova T, Sheppard AM, McNally J, Lowy DR. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 2004;23:1739-48.
63. Takahashi K, Suzuki K. Density-dependent inhibition of growth involves prevention of EGF receptor activation by E-cadherin-mediated cell-cell adhesion. Exp Cell Res 1996;226:214-22.
64. Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R et al. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases. Oncogene 2010;29:2760-71.
65. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ et al. Cadherin switching in human prostate cancer progression. Cancer Res 2000;60:3650-4.
66. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development. Mol Med Today 2000;6:163-9.
67. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 2007;13:7003-11. (Pubitemid 350276881)
68. Haass NK, Smalley KS, Herlyn M. The role of altered cell-cell communication in melanoma progression. J Mol Histol 2004;35:309-18.
69. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001;61:3819-25.
70. Augustine CK, Yoshimoto Y, Gupta M, Zipfel PA, Selim MA, Febbo P et al. Targeting N-cadherin enhances anti-tumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68:3777-84.
71. Johnson JP. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev 1991;10:11-22.
72. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998;50:197-263.
73. Juliano RL. Signal transduction by cell adhesion receptors and the cytoskeleton:functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol 2002;42:283-323.
74. Melnikova VO, Bar-Eli M. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006;19:395-405. (Pubitemid 44326401)
75. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-4.
76. Berezin V. Structure and Function of the Neural Cell Adhesion Molecule NCAM. New York:Springer New York; 2010.
77. Raspadori D, Damiani D, Michieli M, Stocchi R, Gentili S, Gozzetti A et al. CD56 and PGP expression in acute myeloid leukemia:impact on clinical outcome. Haematologica 2002;87:1135-40.
78. Ravandi F, Cortes J, Estrov Z, Thomas D, Giles FJ, Huh YO et al. CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 2002;26:643-9.
79. ZoΠtowska A, Stepifski J, Lewko B, Serkies K, Zamorska B, Roszkiewicz A et al. Neural cell adhesion molecule in breast, colon and lung carcinomas. Arch Immunol Ther Exp (Warsz) 2001;49:171-4.
80. Campodónico PB, de Kier Joffé ED, Urtreger AJ, Lauria LS, Lastiri JM, Puricelli LI et al. The neural cell adhesion molecule is involved in the metastatic capacity in a murine model of lung cancer. Mol Carcinog 49:386-97.
81. Walmod PS, Kolkova K, Berezin V, Bock E. Zippers make signals:NCAM-mediated molecular interactions and signal transduction. Neurochem Res 2004;29:2015-35. (Pubitemid 39663880)
82. Crnic I, Strittmatter K, Cavallaro U, Kopfstein L, Jussila L, Alitalo K et al. Loss of neural cell adhesion molecule induces tumor metastasis by up-regulating lymphangiogenesis. Cancer Res 2004;64:8630-8.
83. Gattenlöhner S, Stühmer T, Leich E, Reinhard M, Etschmann B, Völker HU et al. Specific detection of CD56 (NCAM) isoforms for the identification of aggressive malignant neoplasms with progressive development. Am J Pathol 2009;174:1160-71.
84. Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. Mod Pathol 1998;11:1098-106.
85. Denton KJ, Stretch JR, Gatter KC, Harris AL. A study of adhesion molecules as markers of progression in malignant melanoma. J Pathol 1992;167:187-91.
86. Kraus A, Masat L, Johnson JP. Analysis of the expression of intercellular adhesion molecule-1 and MUC18 on benign and malignant melanocytic lesions using monoclonal antibodies directed against distinct epitopes and recognizing denatured, non-glycosylated antigen. Melanoma Res 1997;7 Suppl 2:S75-81.
87. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 1994;54:2514-20. (Pubitemid 24138750)
88. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. Development of a tissue array for primary melanoma with long-term follow-up:discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 2005;115:367-75.
89. Shih IM, Wang TL, Westra WH. Diagnostic and biological implications of mel-CAM expression in mesenchymal neoplasms. Clin Cancer Res 1996;2:569-75.
90. Anfosso F, Bardin N, Francès V, Vivier E, Camoin-Jau L et al. Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). J Biol Chem 1998;273:26852-6.
91. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA et al. Loss of AP-2 results in up-regulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273:16501-8.
92. Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H et al. Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem 2009;284:28845-55.
93. Mills L, Tellez C, Huang S, Baker C, McCarty M, Green L et al. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. Cancer Res 2002;62:5106-14.
94. Livesey FJ. Netrins and netrin receptors. Cell Mol Life Sci 1999;56:62-8.
95. Rodrigues S, De Wever O, Bruyneel E, Rooney RJ, Gespach C. Opposing roles of netrin-1 and the dependence receptor DCC in cancer cell invasion, tumor growth and metastasis. Oncogene 2007;26:5615-25. (Pubitemid 47267839)
96. Kobayashi H, Boelte KC, Lin PC. Endothelial cell adhesion molecules and cancer progression. Curr Med Chem 2007;14:377-86. (Pubitemid 46299685)
97. Lafrenie RM, Buckner CA, Bewick MA. Cell adhesion and cancer: is there a potential for therapeutic intervention? Expert Opin Ther Targets 2007;11:727-31.
98. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001.
99. McEver RP. Selectins:lectins that initiate cell adhesion under flow. Curr Opin Cell Biol 2002;14:581-6.
100. Humphries MJ, Newham P. The structure of cell-adhesion molecules. Trends Cell Biol 1998;8:78-83.
101. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994;76:301-14.
102. Smith CW. 3. Adhesion molecules and receptors. J Allergy Clin Immunol 2008;121:S375-9;quiz S414.
103. Ehrhardt C, Kneuer C, Bakowsky U. Selectins - an emerging target for drug delivery. Adv Drug Deliv Rev 2004;56:527-49.
104. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007;11:1473-91. (Pubitemid 350200482)
105. Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev 2008;27:19-30.
106. Magnani JL. The discovery, biology, and drug development of sialyl Lea and sialyl Lex. Arch Biochem Biophys 2004;426:122-31.
107. Thomas SN, Tong Z, Stebe KJ, Konstantopoulos K. Identification, characterization and utilization of tumor cell selectin ligands in the design of colon cancer diagnostics. Biorheology 2009;46:207-25.
108. Nooijen PT, Westphal JR, Eggermont AM, Schalkwijk C, Max R, de Waal RM et al. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol 1998;152:679-82.
109. Schmidmaier R, Baumann P. ANTI-ADHESION Evolves To a Promising Therapeutic Concept in Oncology. Curr Med Chem 2008;15:978-90.
110. Dunehoo AL, Anderson M, Majumdar S, Kobayashi N, Berkland C, Siahaan TJ. Cell adhesion molecules for targeted drug delivery. J Pharm Sci 2006;95:1856-72. (Pubitemid 44433019)
111. Williams E, Williams G, Gour BJ, Blaschuk OW, Doherty P. A novel family of cyclic peptide antagonists suggests that N-cadherin specificity is determined by amino acids that flank the HAV motif. J Biol Chem 2000;275:4007-12. (Pubitemid 30094629)
112. Mariotti A, Perotti A, Sessa C, Ruegg C. N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs 2007;16:451-65.
113. Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC et al. Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials 31:2388-98.
114. Grange C, Geninatti-Crich S, Esposito G, Alberti D, Tei L, Bussolat et al. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res 2010;70:2180-90.